Press Release

PhRMA Statement on Open Payments Data Concerns

PhRMA August 26, 2014

Washington, D.C. (August 26, 2014) — Pharmaceutical Research and Manufacturers of America (PhRMA) Assistant General Counsel, John Murphy, issued the following statement regarding the announcement by the Centers for Medicare and Medicaid Services (CMS) to delay publication of a significant portion of data in the open payments database – a database established through the Physician Payments Sunshine Act included in the Affordable Care Act:

“PhRMA supports the Sunshine Act and, since the law was enacted, biopharmaceutical companies have worked diligently to ensure that their data is accurate and submitted in a timely manner so that physicians have sufficient time to review and provide feedback. 

“An analysis of the data that CMS removed from the database found that PhRMA member companies submitted their data in a manner consistent with the reporting rules outlined by the agency. To reconcile the existing data issues, additional guidance from CMS is needed clarifying the reporting regulations. We also ask CMS provide additional transparency around the decision to remove one-third of the data from the site.

“Our industry is committed to working with CMS and the physician community to ensure that all data is accurate, and that proper context is provided to explain how collaborations between companies and physicians can improve patient care and help promote medical innovation.” 

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $550 billion in the search for new treatments and cures, including an estimated $51.1 billion in 2013 alone.

Find PhRMA Online:

Website –
Facebook –
Blog –
Twitter – and
YouTube –

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health emergencies, visit